Performance analysis of Brainstorm Cell Therapeutics (BCLI)
Annual Return
Over the past 3 years, BCLI has had an average annual return of -73.68%, underperforming the benchmark SPY, which returned +20.51% annual.
Over the past 5 years, BCLI has had an average annual return of -58.38%, underperforming the benchmark SPY, which returned +13.50% annual.
Over the past 10 years, BCLI has had an average annual return of -32.23%, underperforming the benchmark SPY, which returned +15.42% annual.
Since Aug 28, 2003, BCLI has had an average annual return of -18.14%, underperforming the benchmark SPY, which returned +11.17% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +35.06% | -75.56% | -44.54% | -83.36% | -59.01% | -11.59% | +5.73% | +20.56% | -9.44% | +54.32% | -11.19% | -39.91% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
| +76.28% | -18.18% | +4.76% | +10.54% | -26.92% | +333.37% | -90.77% | +132.16% | -37.78% | -77.39% | +99% | +212.22% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +12.99% | +11.49% | +36.08% | -34.85% | +20.93% | +0% | +35.06% | ||||||
| 2025 | -19.68% | -12.25% | -21.17% | +2.86% | -13.89% | +0% | -36.13% | +6.06% | -6.67% | -8.16% | -2.22% | -12.50% | -75.56% |
| 2024 | +29.40% | +3.95% | +53.80% | -33.11% | +28.88% | -30.40% | +0.99% | -9.69% | -25.51% | -45.93% | -6.95% | +30.71% | -44.54% |
| 2023 | +10.99% | +24.18% | +46.02% | -12.43% | -1.38% | -27.71% | -10.68% | -7.08% | -88.31% | -23.56% | +82.70% | -2.24% | -83.36% |
| 2022 | -22.00% | -2.25% | +10.16% | -10.71% | -2.00% | -6.11% | -7.26% | +41.42% | +22.10% | -19.46% | -53.66% | -0.61% | -59.01% |
| 2021 | +33.49% | -32.79% | -5.66% | -9.41% | +3.17% | +6.15% | +6.06% | -13.90% | -4.89% | -12.27% | +31.25% | +5.27% | -11.59% |
| 2020 | -4.91% | +71.50% | -33.52% | +32.53% | +21.14% | +50.47% | +20.88% | -6.94% | +34.18% | -40.72% | -44.91% | -18.10% | +5.73% |
| 2019 | +3.38% | +6.53% | +11% | -8.29% | -8.04% | +7.92% | +1.52% | -7.23% | +4.83% | -6.92% | +9.37% | +7.81% | +20.56% |
| 2018 | -11.23% | -11.78% | +2.60% | +4.13% | +52.44% | -22.00% | +5.90% | -4.12% | -3.53% | -14.66% | -4.60% | +14.15% | -9.44% |
| 2017 | +11.80% | +53.17% | -2.30% | -2.83% | -4.36% | +5.07% | +12.28% | -8.58% | -3.29% | +3.65% | -4.69% | -3.68% | +54.32% |
Drawdown analysis of Brainstorm Cell Therapeutics (BCLI)
The maximum drawdown for the BCLI was -99.94%, occurring on Feb 17, 2026. This drawdown has not yet recovered.
The current BCLI drawdown is -99.90%.
Since Aug 28, 2003 BCLI has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.94% | Jan 7, 2005 | 5309 | Feb 17, 2026 | Ongoing | Ongoing | Ongoing |
| -50.00% | Oct 21, 2003 | 147 | May 21, 2004 | 115 | Nov 4, 2004 | 262 |
| -9.00% | Dec 15, 2004 | 14 | Jan 5, 2005 | 1 | Jan 6, 2005 | 15 |
| -7.27% | Oct 3, 2003 | 3 | Oct 8, 2003 | 1 | Oct 9, 2003 | 4 |
| -4.64% | Nov 26, 2004 | 7 | Dec 7, 2004 | 4 | Dec 13, 2004 | 11 |
| -2.29% | Sep 22, 2003 | 8 | Oct 2, 2003 | 1 | Oct 3, 2003 | 9 |